Skip to content

TuHURA Biosciences, Inc. HURA Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
Janux Therapeutics logo
Janux TherapeuticsJANX
Vera Therapeutics logo
Vera TherapeuticsVERA

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s software and technology licenses, net?
TuHURA Biosciences, Inc. (HURA) reported software and technology licenses, net of $33.77K in Q1 2026.